Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Cell Source, Inc. | Director | Common Stock | 115K | $86.2K | $0.75 | Jun 30, 2021 | Direct |
Cell Source, Inc. | Director | Director Stock Option (Right to Buy) | 450K | Aug 19, 2020 | Direct | ||
Kintara Therapeutics, Inc. | Chief Scientific Officer | Options (Right to Buy) | 10.2K | Aug 30, 2023 | Direct | ||
Cell Source, Inc. | Director | Series A Convertible Preferred Stock | 6.67K | Feb 13, 2019 | Direct | ||
Kintara Therapeutics, Inc. | Chief Scientific Officer | Common Stock, par value $0.001 per share | 5.3K | Jan 5, 2023 | Direct | ||
Kintara Therapeutics, Inc. | Chief Scientific Officer | Common Stock, par value $0.001 per share | 1.08K | Jan 5, 2023 | Indirect |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
KTRA | Kintara Therapeutics, Inc. | Aug 30, 2023 | 1 | $0 | 4 | Sep 1, 2023 | Chief Scientific Officer |
KTRA | Kintara Therapeutics, Inc. | Jan 5, 2023 | 1 | $0 | 4 | Jan 6, 2023 | Chief Scientific Officer |
KTRA | Kintara Therapeutics, Inc. | Aug 1, 2022 | 2 | $0 | 4 | Aug 3, 2022 | Chief Scientific Officer |
CLCS | Cell Source, Inc. | Jun 30, 2021 | 1 | $2.23K | 4 | Jul 7, 2021 | Director |
CLCS | Cell Source, Inc. | Feb 13, 2019 | 5 | $59K | 4 | Jun 10, 2021 | Director |